Menu

Recent Interviews

Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


John Jeffrey, CEO, Saturn Oil & Gas Inc.

John Jeffrey
CEO | Saturn Oil & Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary, AB (CAN)

jjeffrey@saturnoil.com

+1-587-392-7900

Saturn Oil & Gas CEO John Jeffrey on the future of the company and ESG


15. January 2020 | 07:42 CET

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical
Photo credits: pixabay.com

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


All analysts convinced of growth course

All analysts - including Commerzbank and Bankhaus Metzler - are convinced that M1 Kliniken will continue to grow at double-digit rates in the coming years and recommend the share as a buy. Five analysts expect M1 Kliniken to break through the EUR 100 million revenue barrier this year (2018: EUR 65 million). The average expectation for net income in 2020 is EUR 9.8 million (2018: EUR 6.6 million).

Sales and profit growth foreseeable

M1 has already laid the foundation for further revenue and profit growth in the current year. In 2019, 12 new specialist centres were opened, significantly more than in previous years (average 6 p.a.). This means that the Group now operates 36 outpatient centres for aesthetic medicine. With Dortmund, Bielefeld, Rostock, Stuttgart II and Frankfurt (M1 Dental), M1 has increased the number of locations in Germany by 5 to 28.

In addition, larger premises were moved into Hamburg and Hanover. At the same time, M1 is specifically increasing the range of treatments offered in the existing specialist centres. For example, aesthetic laser treatments, such as hair removal, are now offered at 20 beauty locations under the "M1 Laser" brand.

Internationalization as growth driver

International expansion was added as an additional growth driver last year. After the first international "M1 Med Beauty" specialist centre for aesthetic medicine was opened in Vienna in December 2018, 7 foreign locations have been added in recent months. In addition to a further location in Austria (Linz), the company has successfully entered the markets in the Netherlands (Amsterdam, Rotterdam), Switzerland (Zurich) and Australia (Melbourne, Sydney, Brisbane).

Project pipeline gives reason to expect dynamic start to 2020

In addition, the project development for 10 further specialist centres - 5 of them in Great Britain alone - has been largely completed. The M1 Group is thus fully on track to achieve its goal: 50 specialist beauty centres by the end of 2020. M1 has already secured the necessary financing in September 2018 through a capital increase.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. December 2020 | 14:16 CET | by Nico Popp

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

  • Medical

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

Read

05. May 2020 | 08:33 CET | by Mario Hose

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

Read

24. April 2020 | 07:36 CET | by Mario Hose

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

Read